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To combat the deleterious effects that oxidation of the sulfur atom in methionine to sulfoxide 2 
may bring, aerobic cells express repair pathways involving methionine sulfoxide reductases 3 
(MSRs) to reverse the above reaction. Here, we show that Trypanosoma brucei, the causative 4 
agent of African trypanosomiasis, expresses two distinct trypanothione-dependent MSRs that 5 
can be distinguished from each other based on sequence, sub-cellular localisation and substrate 6 
preference. One enzyme found in the parasite’s cytosol, shows homology to the MSRA family 7 
of repair proteins and preferentially metabolises the S epimer of methionine sulfoxide. The 8 
second, which contains sequence motifs present in MSRBs, is restricted to the mitochondrion 9 
and can only catalyse reduction of the R form of peptide-bound methionine sulfoxide. The 10 
importance of these proteins to the parasite was demonstrated using functional genomic-based 11 
approaches to produce cells with reduced or elevated expression levels of MSRA, which 12 
exhibited altered susceptibility to exogenous H2O2. These findings identify new reparative 13 
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The Trypanosomatida represent an order of parasitic protozoa belonging to the Class 2 
Kinetoplastidea [1]. They are responsible for several infections in humans with Trypanosoma 3 
brucei and Trypanosoma cruzi causing human African trypanosomiasis (HAT) and Chagas 4 
disease, respectively. In addition, more than 20 Leishmania species can trigger a spectrum of 5 
pathologies collectively termed leishmaniasis. Spread by the hematophagous habits of insect 6 
vectors, these pathogens are endemic throughout tropical and sub-tropical regions of the world 7 
and cause more than 55,000 deaths per year (http://www.dndi.org/). 8 
All organisms living in an aerobic environment are exposed to a range of reactive oxygen 9 
species (ROS) primarily generated as by-products of respiration. These can readily react with 10 
various macromolecules leading to formation of other toxic metabolites and/or damage to the 11 
target. One target that ROS have a considerable effect on are proteins, resulting in oxidation of 12 
certain residues such as cysteine, histidine, tyrosine, and methionine (Met), which can reducing 13 
equivalents into change and, in some cases, modification of protein function [2, 3]. Oxidation 14 
of Met produces methionine sulfoxide (MetSO) that exists as a mixture of two epimers, 15 
methionine-(S)-sulfoxide (Met(S)O) and methionine-(R)-sulfoxide (Met(R)O). To combat the 16 
potentially deleterious effect of these diastereomers, cells express several unrelated enzymes, 17 
known as methionine sulfoxide reductases (MSRs), that catalyse reduction of MetSO back to 18 
Met [4, 5]. These distinct activities can be distinguished based on sequence and substrate 19 
specificity. Metabolism of both free and protein-bound Met(S)SO is performed by methionine 20 
sulfoxide reductase A (MSRA) [6, 7] while reduction of free or protein-bound Met(R)O is 21 
mediated by free methionine-(R)-sulfoxide reductase (fRMSR) or methionine sulfoxide 22 
reductase B (MSRB), respectively [8-10]. The activity of these enzymes is generally driven by 23 
a thioredoxin/thioredoxin reductase-dependent redox cascade that facilitate transfer of 24 
reducing equivalents from NADPH to the MSR, although other molecules such as 25 
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metallothionein or glutaredoxin, may also act as source of reductant [8, 11-14]. The importance 1 
of these pathways has been demonstrated as organisms lacking MSR(s) are more susceptible 2 
to oxidative stress, often have a shortened life span and, in the case of bacterial pathogens, 3 
reduced virulence [7, 15-19]. 4 
In contrast to their mammalian hosts, trypanosomatids lack a raft of enzymes including 5 
Cu/Zn- and Mn-superoxide dismutase (SOD), catalase, selenium-dependent glutathione 6 
peroxidase, glutathione reductase and thioredoxin reductase, activities that help maintain the 7 
redox balance in many other eukaryotic cells. Instead, they express alternative mechanisms that 8 
fulfil the above activities, with many of these proposed as potential targets for 9 
chemotherapeutic intervention. For example, removal of superoxide anions by trypanosomes 10 
and leishmanial parasites is exclusively catalysed by Fe-SOD, enzymes normally found in 11 
bacteria, lower eukaryotes and the chloroplasts of plants, while maintenance of the intracellular 12 
thiol redox homeostasis is centred upon the trypanosomatid-specific molecule trypanothione 13 
[20-22]. In a pathway analogous to the glutathione (GSH)/glutathione reductase system, 14 
trypanothione is maintained in its reduced, dihydrotrypanothione (T(SH)2) form by the activity 15 
of a NADPH-dependent flavoprotein trypanothione reductase (TR) [23, 24]. T(SH)2 then drives 16 
a series of two component cascades, facilitating flux of reducing equivalents into tryparedoxins 17 
(TXNs), GSH or ascorbate which in turn reduce various peroxidases, reductases, glyoxalases 18 
and transferases [25, 26]. 19 
One recipient of the electron flux via the T(SH)2/TXN cascade is MSRA, with analysis of 20 
the T. cruzi and Leishmania major homologues revealing its role as an anti-oxidant enzyme 21 
within the parasite [27, 28]. Here, we report the dissection of two MetSO metabolising 22 
pathways expressed by T. brucei focusing on the biochemical properties, subcellular 23 




Materials and Methods 1 
Parasites. 2 
Bloodstream form (BSF) T. brucei SMB and 2T1 trypomastigotes that constitutively express 3 
the tetracycline repressor protein were grown at 37oC under a 5% (v/v) CO2 atmosphere in 4 
modified Iscove's medium containing 2.5 µg ml-1 G418 (SMB) or 1 µg ml-1 phleomycin (2T1) 5 
[29-31]. Transformed parasites were maintained in this growth medium supplemented with 2.5 6 
µg mL-1 hygromycin. DNA and total RNA were extracted from parasites using the DNeasy® 7 
Tissue and RNeasy® mini kits (Qiagen), respectively. T. brucei genes that encode for TbmsrA 8 
and TbmsrB were identified from the TriTrypDB (http://tritrypdb.org/tritrypdb/) database [32]: 9 
TriTrypDB Gene ID Tb927.8.550 and Tb927.11.11930.1 for TbmsrA and TbmsrB, 10 
respectively.  11 
 12 
Protein purification. 13 
DNA fragments containing the full length coding sequence of TbmsrA and a version of TbmsrB 14 
lacking its 5’ (1-130 bp) region were amplified from T. brucei genomic DNA using the primer 15 
combinations TbMSRA-1/TbMSRA-2 or TbMSRB-1/TbMSRB-2 (Table 1), respectively. The 16 
products were digested with BamHI/HindIII (TbmsrA) or BglII/HindIII (TbmsrB) and cloned 17 
into the BamHI/HindIII sites of the expression vector pTrcHis-C (Invitrogen). 18 
Protein expression and purification were conducted as previously described [27]. Overnight 19 
cultures of E. coli BL21 (DE3) transformed with the expression plasmid were diluted 1/100 in 20 
Terrific Broth (12 g l− 1 peptone, 24 g l− 1 yeast extract, 4 mL l− 1 glycerol, 2.3 g l− 1 KH2PO4, 21 
12.5 g l− 1 K2HPO4, pH 7.0) supplemented with 100 μg ml
− 1 ampicillin and grown to 22 
exponential phase at 37ºC with aeration. Expression of the HIS-tagged recombinant protein 23 
was induced with 0.5 mM IPTG, followed by incubation at 25 °C. After 4 hours, cells were 24 
harvested and bacterial pellets stored at −20 °C. Purification of recombinant protein was 25 
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performed using a Ni2+–HiTrap column (GE Healthcare). Briefly, the bacterial pellet was 1 
resuspended in binding buffer (20 mM Tris.HCl, pH 7.5, 10 mM imidazole and 400 mM NaCl) 2 
and disrupted by sonication. The lysate was centrifuged (10,000g, 30 min) to remove cell 3 
debris. The resultant crude extract was loaded onto a Ni2+–HiTrap column (1 ml) previously 4 
equilibrated with binding buffer. After washing with 15 bead volumes of binding buffer plus 5 
30 mM imidazole, the recombinant protein was eluted with elution buffer (20 mM Tris.HCl, 6 
pH 7.5, 400 mM NaCl, 300 mM imidazole). Purified enzyme fractions were pooled, 7 
concentrated by ultrafiltration, and stored at -80 °C in 20 mM Tris.HCl pH 7.5; 100 mM NaCl 8 
and 10% (v/v) glycerol. 9 
  10 
Enzyme activity. 11 
MSR activity was measured by monitoring NADPH oxidation at 340 nm by means of a coupled 12 
assay that guaranteed the regeneration of TXNI to its reduced form [27]. All enzyme assays 13 
were performed at 30 °C using a Multiskan Ascent one-channel vertical light-path filter 14 
photometer (Thermo Electron Co.). The reaction mixture (final volume of 50 μl) contained 15 
(unless otherwise specified) 100 mM Tris.HCl, pH 7.5, 2 mM EDTA, 300 μM NADPH, 2 U 16 
ml− 1 TcTR, 100 μM T(SH)2 (Bachem), 10 μM TcTXNI, and the respective MSR included in a 17 
specific range of concentrations (0.5–3.5 μM TbMSRA or TbMSRB). TcTXN1 was used in 18 
these assays as it was readily available in our laboratory and was assumed to function in an 19 
equivalent manner to its T. brucei counterpart (TcTXNI and TbTXN1 share 62 % identity [33]). 20 
Reactions were started by the addition of 5 mM MetSO substrate (racemic N-acetyl MetSO 21 
(N-AcMetSO) (Bachem), racemic L-MetSO (Sigma-Aldrich), L-Met(S)SO, L-Met(R)SO or N-22 
Acetyl Met(R)SO: The enantiomers were prepared as previously described [34]). Addition of 23 
EDTA into the reaction did not affect TbMSRB activity and as such was included in assays to 24 
minimise heavy metal mediated thiol oxidation. 25 
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For TbMSRB steady-state kinetic analysis, the assay was performed using 20–2500 μM N-1 
AcMet(R)SO and 0.5–20 μM TcTXNI. Kinetic data were plotted as initial velocity (μM min− 1) 2 
versus substrate concentration (μM). The kinetic constants were acquired by fitting the data 3 
with a nonlinear least-squares formula and the Michaelis–Menten equation using the program 4 
Origin 7.0. Kinetic constants were the means of at least three independent sets of data, and they 5 
were reproducible within ± 10%. 6 
 7 
Yeast complementation. 8 
In vivo MSR activity of T. brucei enzymes was checked using the triple msr mutant GY202 9 
(ΔmsrA ΔmsrB ΔfRmsr) [18]. The Saccharomyces cerevisiae GY202 strain was transformed 10 
with parental plasmid p425GPD, p425GPD–TbmsrA or p425GPD–TbmsrB and selected for 11 
leucine prototrophy on Yeast Nitrogen Based (YNB)-agar medium supplemented with L-Met 12 
[35]. To perform the complement assay, each recombinant clone was cultivated on YNB-agar 13 
medium supplemented with L-Met, a L-MetSO racemic mix, L-Met(S)SO-or L-Met(R)SO (all 14 
100 µM) at 30 °C until growth was visualized. 15 
 16 
RNA interference. 17 
Fragments corresponding to internal sequences of TbmsrA (491 bp) and TbmsrB (426bp) were 18 
amplified from T. brucei genomic DNA using the primers TbMSRA-3/TbMSRA-4 or 19 
TbMSRB-3/TbMSRB-4 (Table 1), respectively. The products were digested with BamHI/XhoI 20 
(TbmsrA) or BglII/XhoI (TbmsrB) and cloned into the BamHI/XhoI sites of the vector p2T7Ti 21 
[36]. In this vector, the inserted DNA is flanked by two opposing T7 promoters with each 22 
promoter under the control of a tetracycline operator. Constructs were linearised with NotI, 23 
electroporated into T. brucei SMB parasites and transformants selected using hygromycin [37]. 24 
Induction of RNA interference (RNAi) was initiated by adding 1 µg ml-1 tetracycline to the 25 
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culture. To demonstrate down regulation of the TbmsrA or TbmsrB transcript, cDNA generated 1 
using the Superscript® VILOTM cDNA synthesis kit (ThermoFisher Scientific) from total RNA 2 
extracted from cells induced to undergo RNAi for 48 hours was subject to qPCR using the 3 
QuantiTect SYBR® Green PCR kit (Qiagen) and the primer combinations TbMSRA-4 
7/TbMSRA-2 or TbMSRB-7/TbMSRB-2 (Table 1), respectively. All reactions were performed 5 
in triplicate on two independently generated cDNA samples. From the resultant sigmoidal 6 
curves, the cycle threshold (CT) value was determined and normalized against standardized 7 
control (Tbtert; primer combination TbTERT-R and TbTERT-F) amplified in parallel [38] 8 
using the comparative CT method [39].  9 
 10 
Trypanosomal epitope tagging vectors. 11 
The full length coding sequences of TbmsrA and TbmsrB were amplified from genomic DNA 12 
using the primer combinations TbMSRA-5/TbMSRA-6 or TbMSRB-5/TbMSRB-6 (Table 1), 13 
respectively. The products were digested with HindIII/XbaI and cloned into the corresponding 14 
sites of the vectors pRPaC-GFP or BSF-9e10 [31, 40]. The cloning was carried out such that the 15 
sequences coding for the green fluorescence protein (GFP) or 9E10 epitope from the human c-16 
myc protein were inserted in-frame at the 3’ end of the Tbmsr-derived DNA fragment. The 17 
AscI digested constructs were introduced into T. brucei 2T1 and transformants selected using 18 
hygromycin. Expression of the recombinant protein in the parasite was initiated by adding 1 19 
µg ml-1 tetracycline to the culture. 20 
 21 
Localisation. 22 
BSF trypanosomes expressing TbMSRB-GFP were suspended at 5 x 106 cells ml-1 in medium 23 
containing 100 nM MitoTracker Red (Molecular Probes) and incubated at 37oC for 5 min. Cells 24 
were washed twice in phosphate buffered saline (PBS), fixed in 2% (w/v) 25 
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paraformaldehyde/PBS then washed again in PBS. Aliquots of the cell suspension (105 cells) 1 
were then air dried onto microscope slides. Parasite DNA was stained with Vectashield 2 
containing 200 pM 4, 6-diamidino-2-phenylindole (DAPI) (Vector Laboratories Ltd) and slides 3 
were viewed using a Leica SP5 confocal microscope. BSF trypanosomes expressing TbMSRA-4 
GFP were treated similarly except the MitoTracker Red step was omitted. 5 
 6 
Peroxide sensitivity experiments. 7 
T. brucei BSF parasites were seeded at 1 x 104 ml-1 in 200 µl growth medium containing 8 
different concentrations of H2O2 and tetracycline (1 µg ml
-1), where appropriate. After 9 
incubation at 37oC for 3 days 2.5 µg resazurin (Sigma Aldrich) was added to each culture and 10 
the plates incubated for a further 8 hours. Cell densities were determined by monitoring the 11 
fluorescence of each culture using a Gemini Fluorescent Plate Reader (Molecular Devices 12 
(UK) Ltd, Wokingham, UK) at an excitation λ = 530 nm, emission λ = 585 nm and a filter cut 13 
off at 550 nm, and EC50 values established using the non-linear regression tool on GraphPad 14 
Prism (GraphPad Software Inc.). 15 
 16 
Results 17 
Trypanosoma brucei express functional methionine sulfoxide reductases. 18 
Reduction of the MetSO stereoisomers to Met is mediated by distinct MSRs. Analysis of the 19 
T. brucei genome database [32] identified two hypothetical genes that encode for two such 20 
activities. One 543 bp open reading frame (Tb927.8.550; designated as TbmsrA) located on 21 
chromosome 8 has potential to be translated into a 20 kDa protein related to peptide MSRs, a 22 
family of enzymes that mediate metabolism of Met(S)SO [6, 7]. The second 423 bp open 23 
reading frame (Tb927.11.11930.1; designated as TbmsrB) located on chromosome 11, has 24 
potential to encode for a 16 kDa protein that has homology to SelR enzymes which catalyse 25 
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reduction of Met(R)SO [8]. The two T. brucei MSRs share no homology but do have 1 
approximately 60% identity to their trypanosomal and leishmanial orthologues (Figure 1). 2 
When compared to other sequences, TbMSRA exhibits similar % identities (35-40%) to 3 
counterparts from plants, humans, fungi and bacteria while TbMSRB has higher identity to 4 
SelR proteins of plant (~48%) and fungal (~38%) origin relative to bacterial and human (both 5 
~25%) enzymes. Based on sequence, TbMSRA is composed of a single peptide methionine 6 
sulfoxide reductase (PF01625) domain that contains a characteristic GCFWG motif [5]. In 7 
MSRAs from other organisms, cysteine (Cys13 in TbMSRA) at this site plays a key role to 8 
catalyse reduction of MetSO, with a second conserved cysteine (Cys171 in TbMSRA) found 9 
towards the carboxyl terminal helping maintain the catalytic cysteine in its reduced, active form 10 
(Figure 1A). Further searches using localisation prediction algorithms (e.g. PSORT II) 11 
indicates that TbMSRA lacks any classical sub-cellular localisation signals, suggesting that 12 
this enzyme is mostly likely found in the parasite’s cytoplasm. Similarly, TbMSRB is 13 
composed of a single SelR (PF01641) domain containing several conserved cysteines [5]. 14 
MSRBs from other organisms also contains several conserved cysteine (or selenocysteine) 15 
residues. These are involved in oxidoreductase activity (Cys117 and Cys171 in TbMSRB), 16 
with the latter cysteine (or selenocysteine) catalysing substrate reduction and the former 17 
functioning to maintain the catalytic cysteine in its reduced, active form, or zinc co-factor 18 
binding (Cys99, Cys102, Cys145 and Cys148 in TbMSRB) (Figure 1B). Here, localisation 19 
prediction algorithms (e.g. PSORT II, iPSORT and TargetP) suggest that the amino terminal 20 
of this enzyme, characterized by the presence of hydrophobic and basic amino acids and a lack 21 
of acidic residues, may function as a mitochondrial targeting signal. 22 
To investigate whether the trypanosomal proteins can function as MSRs, the DNA 23 
sequences encoding for their catalytic domains were cloned into pTrcHis-C (Invitrogen) and 24 
expressed in E. coli. In this system, the recombinant enzymes were tagged at their amino 25 
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terminus with a histidine-rich sequence and an epitope detectable with the anti-Xpress 1 
monoclonal antibody (Invitrogen). For TbMSRA, expression of the full length gene generated 2 
soluble recombinant protein. In contrast, the only construct that gave functional TbMSRB was 3 
a deletion derivative in which the recombinant protein lacked the amino terminal, 4 
mitochondrial targeting extension (Figure 1B). After induction with isopropyl β-D-5 
thiogalactoside, these constructs generated ~24 and ~21 kDa proteins corresponding to HIS-6 
tagged TbMSRA and TbMSRB respectively, proteins that could be readily purified after one 7 
round of affinity chromatography on a nickel-HiTRAP column (Figure 2A). 8 
Previous studies on trypanosomal MSRA revealed that their activity is driven by a TXN-9 
dependent cascade, with NADPH being the source of reducing equivalents [27]. Using a 10 
coupled assay that guaranteed regeneration of TXN, the activity of TbMSRA and TbMSRB 11 
was monitored by following NADPH oxidation at 340 nm (Figure 2B). Under the conditions 12 
employed, both enzymes were able to reduce N-AcMetSO confirming that they exhibited MSR 13 
activities, with the rate of substrate reduction being dependent upon TbMSR concentration 14 
(Figure 2B). When any of the constituents (TR, T(SH)2, TXN or TbMSRA/TbMSRB) of the 15 
pathway were missing, no activity was observed. TbMSRA was able to metabolise N-16 
AcMetSO more readily than TbMSRB with TbMSRA exhibiting an apparent kcat >110-fold 17 
higher than that of TbMSRB for this substrate: TbMSRA and TbMSRB display apparent kcat 18 
values of 12.3 and 0.11 min-1, respectively, towards N-AcMetSO. 19 
 20 
TbMSRs display different MetSO isomer specificity. 21 
To determine TbMSRA or TbMSRB specificity, their activity was followed using different 22 
MetSO stereoisomers as substrate and compared to reactions using a MetSO racemic mix 23 
(Figure 2C). In agreement with MSRs from other organisms [5], TbMSRA could only 24 
metabolise L-Met(S)SO while TbMSRB was specific for towards L-Met(R)SO. 25 
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To investigate substrate specificity further and provide additional evidence that the two T. 1 
brucei enzymes do function as MSRs, the TbmsrA and TbmsrB DNA sequences in pTrcHis-C 2 
were transferred into the yeast expression vector p425-GPD. The resultant plasmids were 3 
transformed into a S. cerevisiae strain lacking three MSR enzymes and growth of the modified 4 
yeast on YNB agar plus dextrose agar supplemented with Met or different MetSO monitored 5 
(Figure 3). On medium containing L-Met, the growth of all fungal line was supported. In 6 
contrast, only strains expressing TbMSRA or TbMSRB could grow on medium where L-7 
MetSO racemate was the sole source of L-Met. When using L-Met(S)SO or L-Met(R)SO 8 
supplemented YNB, only S. cerevisiae transformed with the TbMSRA could grow on the 9 
former medium whereas only yeast expressing TbMSRB displayed strong growth on the latter. 10 
Previous work revealed that TbMSRA activity could be readily saturated by TXN and L-11 
Met(S)SO [27]. Here, we showed that free L-Met(R)SO was not efficiently metabolised by 12 
TbMSRB indicating that this was not the physiological substrate for this enzyme (Table 1). 13 
Instead TbMSRB displayed Michaelis-Menten type kinetics towards TXN and N-AcMet(R)SO 14 
although metabolism of this particular substrate via this pathway was extremely low (kcat of 15 
0.085 min-1) (Figure 2D). Comparison of Km values suggests that the rate limiting step within 16 
this pathway may be the interaction of TbMSRB with N-AcMet(R)SO (TbMSRB has a Km of 17 
1.8 ± 0.3 µM towards TXN and a Km of 429 ± 58 µM towards N-AcMet(R)SO). These low 18 
kinetic values are typical for those reported for bacterial, plant and mammalian MSRBs [41-19 
43] while the ability of the parasite enzyme to metabolise N-AcMet(R)SO indicates that it can 20 
effectively reduce protein bound Met(R)SO: this form of MetSO is often used as substrate to 21 
test for peptide bound MSR activity [44]. 22 
 23 
TbMSRs are targeted to different cellular localisations. 24 
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The subcellular location of the trypanosomal MSRs was examined by expressing GFP-tagged 1 
versions of each enzyme in BSF parasites. The DNA sequences encoding for TbMSRA and 2 
TbMSRB were amplified then cloned in-frame and upstream of the GFP gene in a 3 
trypanosomal vector that facilitated tetracycline inducible gene expression. The localisation 4 
constructs were electroporated into T. brucei and recombinant parasites selected. 5 
To induce expression of the tagged protein, cells were incubated in the presence of 6 
tetracycline for 48 hours. The parasites were then examined by western blotting using an 7 
antibody against GFP (Figure 4A), with each extract containing a single band of the expected 8 
size (bands of ~48 and ~45 kDa were observed in TbMSRA-GFP or TbMSRB-GFP containing 9 
lanes), or were fixed and examined by confocal microscopy (Figure 4C and D). For T. brucei 10 
induced to express tagged TbMSRA, a fluorescence signal was observed throughout the main 11 
body of the cell but absent from the nucleus indicating that this protein is found in the parasite’s 12 
cytoplasm (Figure 4C). In contrast, for parasites expressing TbMSRB-GFP, a lattice-like 13 
structure spread throughout the cell and reminiscent of the pattern reported for proteins that 14 
localise to the parasite’s large, single mitochondrion, was observed (Figure 4D). To confirm 15 
this, cells were co-stained with the mitochondrial dye, MitoTracker. When the images were 16 
superimposed, a pattern of co-localization (yellow staining) was noted indicating that TbMSRB 17 
was located in the same compartment as MitoTracker. When cells expressing untagged GFP 18 
were analysed, fluorescence was detected throughout the whole cell (Figure 4B). The above 19 
localisation patterns were observed by immunofluorescence studies using parasites expressing 20 
TbMSRA or B variants tagged at their carboxyl terminal with the 9E10 epitope from the human 21 
c-myc protein (see below). 22 
 23 
Functional Analysis of TbMSRs in T. brucei. 24 
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To assess the importance of MSR activity to BSF T. brucei, an RNAi-based approach was 1 
employed. DNA fragments corresponding to the central regions of TbmsrA and TbmsrB were 2 
amplified and cloned into the vector p2T7Ti. The RNAi constructs were transformed into T. 3 
brucei and recombinant parasites selected. 4 
The effect of inducing RNAi was examined by following the cell density of tetracycline-5 
treated cultures over a 4 day period and compared against untreated controls (Figure 5A). In 6 
the absence of RNAi, all recombinant cell lines were found to grow at roughly the same rate 7 
as wild type control cells. For cells undergoing RNAi targeting the TbmsrA transcript, no 8 
significant difference in rate of growth was observed over the initial 24 hour period (Figure 9 
5B). However, over the following 24 hours, a dramatic and reproducible reduction in the cell 10 
density was observed in all replicates and clones tested, with this correlating to ~75% fall in 11 
the TbmsrA transcript, as judged by qPCR. Further, the presence of cell debris was noted in 12 
these cultures, suggestive that a proportion of the parasite population had undergone lysis, 13 
while any remaining viable cells exhibited reduced movement. From 48 hours onwards, an 14 
outgrowth of viable parasites were observed in all replicates, a type of reversion previously 15 
observed when targeting transcripts important to the growth of BSF T. brucei [36, 45, 46].  16 
In contrast, cells undergoing RNAi targeting the TbmsrB transcript continued to grow 17 
throughout the entire period albeit with a reduced rate: over the first 24 hours, the growth rate 18 
of tetracycline-treated cells was roughly half that of untreated cultures with this falling further 19 
to approximately 20% in the next 24 hours (Figure 5B). Over the subsequent 48 to 72 hours, 20 
an outgrowth of viable parasites were observed. 21 
Alteration of MSR expression levels in other organisms has shown that they play an 22 
important role in protecting cells from exogenous oxidants [7, 15, 19, 27, 28]. Here, we 23 
investigated whether down-regulation of the trypanosomal MSR transcripts altered parasite 24 
susceptibility to H2O2. Tetracycline induced and non-induced cells harbouring the TbmsrA or 25 
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TbmsrB RNAi constructs were grown in the presence of oxidant and the effective compound 1 
concentration that inhibits parasite growth by 50% (EC50) determined (Figure 5C). For cells 2 
expressing reduced levels of TbMSRB, no significant difference in parasite sensitivity was 3 
observed: the EC50 values ranged from 210 to 225 µM. In contrast, recombinant T. brucei 4 
induced to undergo RNAi targeting the TbmsrA transcript were approximately 2-fold more 5 
susceptible to H2O2 than controls: the EC50 of non-induced RNAi parasites was 204.7 ± 9.4 µM 6 
in comparison to tetracycline treated cells that exhibited an EC50 of 111.4 ± 13.5 µM. 7 
 As parasites with reduced levels of TbmsrA are more susceptible to oxidative stress, we 8 
tested whether MSR overexpression leads to resistance. TbmsrA and TbmsrB, minus their 9 
STOP codon, were amplified then cloned in-frame and upstream of the DNA sequence 10 
encoding for the 9E10 epitope from the human c-myc protein in a trypanosomal vector that 11 
facilitated tetracycline inducible gene expression. The constructs were introduced into T. brucei 12 
and recombinant parasites selected. To verify expression of the tagged TbMSRs, cell extracts 13 
generated from parasites cultured in the presence of tetracycline for 48 hours were examined 14 
by western blotting using an antibody against c-myc epitope (Figure 6A). A single band was 15 
observed in lanes where TbMSRA-9e10 (~21 kDa) or TbMSRB-9e10 (~20kDa) expression 16 
had been induced. Tetracycline treated and untreated T. brucei were then grown in the presence 17 
of H2O2 and EC50s determined (Figure 6B). For cells expressing TbMSRB-9e10, no significant 18 
difference in parasite sensitivity was observed. When these studies were extended to TbMSRA, 19 
parasites expressing the c-myc-tagged enzyme were 1.5-fold more resistant to H2O2 than 20 
controls: the EC50 of non-induced parasites was 212.9 ± 7.7 µM in comparison to tetracycline 21 





Throughout its life cycle, T. brucei is continually exposed to ROS. To combat their 1 
detrimental effects, this parasite expresses a series of novel protection strategies that 2 
collectively constituent this pathogen’s oxidative defence system. As these mechanisms are 3 
distinct from those of its mammalian host [21, 22, 47-49], with several components being 4 
essential for growth of the medically relevant parasite stage, they are viewed as potential targets 5 
for development of new HAT chemotherapies [21, 36, 49, 50]. Here, we report the 6 
characterisation of two additional components of the trypanosomal oxidative defence system, 7 
showing that T. brucei expresses two structurally unrelated MSRs (TbMSRA and TbMSRB) 8 
that can be distinguished on the basis of their sequence, substrate specificity and sub-cellular 9 
localisation. 10 
Although functionally related, TbMSRA and TbMSRB share no significant sequence 11 
homology with this diversity conferring difference in substrate specificities. In the case of 12 
TbMSRA, the presence of a GCFWG motif in its sequence coupled with it being only able to 13 
metabolise the S epimer of MetSO establishes this as a member of the peptide methionine 14 
sulfoxide reductase, or MSRA, family of antioxidant proteins (Figures 1A, 2 and 3). In contrast, 15 
TbMSRB contains a domain structure that places it in the SelR, or MRSB, group of methionine 16 
sulfoxide reductases, with enzymatic and phenotypic screening showing that this parasite 17 
oxidoreductase can only mediate conversion of peptide-bound Met(R)SO to Met (Figures 1B, 18 
2 and 3).  19 
Based on sequence and substrate specificity, the two parasite enzymes are typical members 20 
of the MSRA or MRSB clades although they are different in relation to the pathways that 21 
facilitate their reduction. In many instances, the concerted action of thioredoxin reductase, 22 
thioredoxin and MSR act as intermediaries to shuttle reducing equivalents from NADPH to 23 
MetSO [11]. As trypanosomes lack thioredoxin reductase this pathway cannot operate in T. 24 
brucei. In the case of TbMSRA, its in vitro activity is dependent upon TR and trypanothione. 25 
17 
 
Using NADPH as electron donor, these parasite specific factors fulfil the role of 'thioredoxin 1 
reductase', functioning to maintain TXN in its reduced state [51], with reducing equivalents 2 
then transferred onto Met(S)SO to form Met via the trypanosomal MSR (Fig. 2D) [27]. Steady 3 
state kinetics indicate that the rate limiting step of this pathway appears to be the TbMSRA 4 
mediated reduction of free Met(S)SO to Met, a trait noted for MSRAs from other organisms 5 
[27, 52-54]. As all components of this cascade are widely distributed throughout the parasite 6 
cytosol (Fig. 4C) [47, 55] and that TbMSRA exhibits reasonable kinetics towards both TXN 7 
and free Met(S)SO, it is hypothesized that the above pathway functions within T. brucei, acting 8 
to repair damaged Met, specifically free Met(S)SO, at this particular subcellular site. 9 
Intriguingly, our yeast complementation studies indicate that TbMSRA (and TbMSRB) can 10 
utilize non-trypanothione redox cascades as source of reducing equivalents suggesting that the 11 
activity of these enzymes within the trypanosome may be driven by an alternative system to 12 
that described above. This is analogous to the situation seen with other tryparedoxin-dependent 13 
enzymes, including the tryparedoxin peroxidases, which can exploit different 14 
thioredoxin/thioredoxin-like molecules as electron donor [48, 56]. We postulate that the 15 
trypanosomal MSRs are able to interact with the yeast thioredoxin system and complement for 16 
the appropriate fungal mutation to produce the observed growth phenotype. 17 
In contrast, the pathway that operates to maintain TbMSRB in its reduced state is unclear. 18 
Biochemical studies on recombinant enzyme has shown that the TR/T[SH]2/TXN system can 19 
support TbMSRB activity resulting in slow turnover of N-AcMet(R)SO (Fig. 2). The kinetic 20 
values exhibited by the parasite protein to both TXN and MetSO are on par with those noted 21 
for other MSRBs, with the rate of N-AcMet(R)SO reduction limited by the enzyme/substrate 22 
interaction [8, 57]. Such observations, coupled with the MSRBs preference to bind and 23 
metabolise protein-bound Met(R)SO, has led to the idea that free MetSO may not be the major 24 
physiological substrate for these reductases [8] and may account for the fact that some 25 
18 
 
organisms have evolved other free Met(R)SO metabolising activities (e.g. fRMSRs), with 1 
turnover of this particular substrate taking place at an appreciably faster rate than MSRBs [9, 2 
10]. Further, the components that support the trypanothione-dependent, TbMSRB reduction 3 
cascade are not present at the same cellular site: TR and TbMSRB are restricted to the cytosol 4 
and mitochondrion, respectively, while TXNI is apparently found across both sites (Fig. 4B) 5 
[47, 55]. By implication, either TbMSRB activity is supported by an unidentified pathway 6 
found entirely within the parasite mitochondrion or the TR/T[SH]2/TXN redox cascade is split 7 
across different cellular compartments, with comparative analysis indicating that the thiol 8 
constituent being the transferable factor. In other eukaryotic cells, GSH is maintained at high 9 
(mM) levels in the mitochondrial lumen even though this organelle lacks the biosynthetic 10 
machinery to make this tripeptide. Instead, cytosolic pools of GSH are transferred into 11 
mitochondria via several transporters which may include dicarboxylate and 2-oxoglutarate 12 
carriers [58-60]. If an equivalent T[SH]2 translocation mechanism(s) does function in 13 
trypanosomes then given the unique properties of the parasite specific thiol, any transport 14 
system would be mechanistically distinct from that which operates in the transfer of GSH and 15 
as such would be of particular interest as a target(s) for chemotherapy. Once in the 16 
mitochondrion, T[SH]2 can then facilitate transfer of reducing equivalents via TXN and 17 
TbMSRB to Met(R)SO. Intriguingly, data released as part of the TrypTag project [61] indicates 18 
that trypanosomes express a classical thioredoxin (Tb927.9.3370 on TriTrypDB [32]) which 19 
can be readily reduced by T(SH)2 [62, 63], present throughout the parasite mitochondrion. If 20 
correct, this may also function as an intermediary in shuttling reducing equivalents from 21 
T[SH]2 to TbMSRB. 22 
Our data shows that TbMSRA and TbMSRB are located in the T. brucei cytoplasm and 23 
mitochondrion respectively, a distribution also observed with the S. cerevisiae counterparts 24 
(Figure 4) [64]. Why trypanosomes and yeast target these two enzymes to only these sites is 25 
19 
 
unclear given that mammalian cells possess multiple isoforms of each enzyme type at different 1 
sub-cellular sites (mammalian cells express cytosolic, mitochondrial and nuclear versions of 2 
MSRA and MSRB while an isoform of the latter is also present in the endoplasmic reticulum 3 
[65-67]). Taking into consideration their substrate specificity, the specific localisation 4 
displayed by TbMSRA and TbMSRB raises a number of interesting questions such as how is 5 
free or protein bound Met(S)SO metabolised in parasite organelles and how is free or protein 6 
bound Met(R)SO detoxified at non-mitochondrial sites. Part of this may be attributed to 7 
uncharacterised activities (e.g. T. brucei appears to have potential to encode for a cytoplasmic 8 
fRMSR (Tb927.5.1250 on TriTrypDB)) or could reflect the importance of various MetSO 9 
forms in different compartments of the cell (e.g. it may be favourable to export free MetSO 10 
epimers out of the mitochondrion into the cytoplasm to facilitate conversion back to Met, rather 11 
than carrying out this repair within the organelle).  12 
MSRs represent key components in an organism’s oxidative defence armoury, functioning 13 
in processes such as bacterial and protozoal virulence [7, 28, 68-70] and ageing [16, 17, 71]. 14 
To evaluate the importance of trypanosomal enzymes to T. brucei, functional genomic 15 
approaches were used to generate parasite lines expressing altered levels of each reductase. 16 
Using RNAi, each enzyme was shown to be important but not essential for the growth of 17 
bloodstream form parasites (Fig. 5). For trypanosomes engineered to express reduced levels of 18 
the TbmsrA transcript, the stalling of parasite growth was accompanied by an increased 19 
susceptibility to exogenous H2O2 with the reciprocal phenotype observed in cells engineered 20 
to over express this enzyme. In contrast, the reduction in cell growth observed when targeting 21 
the TbmsrB or the elevated expression of this reductase in T. brucei did not affect parasite 22 
sensitivity to H2O2. The observed susceptibility phenotypes suggest that the amount of 23 
exogenous oxidant added to cultures is sufficient to promote MetSO formation in targets found 24 
in the parasite’s cytosol, damage that can be readily repaired by TbMSRA. However, these 25 
20 
 
peroxide levels are not sufficient to cause significant Met oxidation in the trypanosomal 1 
mitochondrion, presumably because this oxidant is detoxified by the various tryparedoxin 2 
peroxidase systems expressed by T. brucei [47, 49]. 3 
In summary, we have demonstrated that T. brucei expresses cytosolic and mitochondrial 4 
methionine sulfoxide reducing pathways which together constitute a new arm of this parasite’s 5 
oxidative reparative defence system. As the redox cascades associated with these activities rely 6 
upon trypanosome-specific factors and that the activity of the terminal reductase is important 7 
for pathogen growth, these mechanisms may have potential as chemotherapeutic targets. 8 
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Table 1. Oligonucleotides used in this study. The sequences in lower case italics correspond 2 










TbmsrA TbMSRA-1 aaaggatccTGAACCCAAATGCTGTTGCTA 
 TbMSRA-2 gggaagcttCCATTCACCAGTAGAGACGGT 
   
TbmsrB TbMSRB-1 aaaagatctTGACACACTGCGCAAGTAAGA 
 TbMSRB-2 aaaaagcttTTACTTCTCGGATTGAAAACG 
   
RNAi TbmsrA TbMSRA-3 aaaggatccACTTTTGCTGCAGGTTGCTT 
 TbMSRA-4 aaactcgagAATACCCATTGGGGTTTTCC 
   
TbmsrB TbMSRB-3 aaaagatctGCCCTCTTATTTTTCCTGCC 
 TbMSRB-4 aaactcgagCGTTCGTTAGGTGGTGGATT 
   
Localisation TbmsrA TbMSRA-5 aaaaagcttATGAACCCAAATGCTGTTGCT 
 TbMSRA-6 aaatctagaCCAGTAGAGACGGTGTGCACA 
   
TbmsrB TbMSRB-5 aaaaagcttATGCGCAGCAGGAACCTGTCC 
 TbMSRB-6 aaatctagaCTTCTCGGATTGAAAACGAAT 
   
qPCR TbmsrA TbMSRA-7 TAGTAGTGCTAAGGTTGTAAC 
    
 TbmsrB TbMSRB-7 ACGGAAATTTTATGCAATGCG 
    
 Tbtert Tbtert-F AGGAACTGTCACGGAGTTTGC 
  Tbtert-R GAGCGTGTGACTTCCGAAGG 
  4 
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Figure legends 1 
Figure 1. Sequence analysis of T. brucei methionine sulfoxide reductases. (A). Alignment 2 
of MSRA sequences from T. brucei (AAZ12826), T. cruzi (EAN83377), Leishmania major 3 
(CAJ07082), Saccharomyces cerevisiae (NP_010960), Escherichia coli (WP_044721421), 4 
Arabidopsis thaliana (NP_56893) and Homo sapiens (NP_036463). Residues that are highly 5 
or moderately conserved are highlighted in black or grey, respectively. The catalytic (C13; 6 
triangle) and recycling (C171; diamond) cysteines are highlighted [5]. (B). Alignment of 7 
MSRB sequences from T. brucei (XP_829255), T. cruzi (XP_817746), Leishmania major 8 
(XP_001684552), Saccharomyces cerevisiae (NP_009897), Escherichia coli (AE016761_217) 9 
and Arabidopsis thaliana (NP_193915). Residues that are highly or moderately conserved are 10 
highlighted in black or grey, respectively. The putative amino terminal mitochondrial targeting 11 
sequence in the T. brucei MSRB sequence (boxed), the catalytic (C171; triangle), recycling 12 
(C117; diamond) and zinc binding (C99, C102, C145 and C148; asterisk) cysteines are all 13 
highlighted [5]. For both TbMSRA and B, the arrows corresponds to the primers used for 14 
expression of the recombinant protein (Experimental Procedures). 15 
 16 
Figure 2. T. brucei expresses functional methionine sulfoxide reductases. (A). Coomassie-17 
stained SDS-PAGE gel (15%) containing size standards (in kDa; lane M) and purified, 18 
recombinant TbMSRA (lane 1) and TbMSRB (Lane 2). (B). MSR activity of TbMSRA or 19 
TbMSRB was followed by monitoring NADPH oxidation at 340 nm using a coupled assay that 20 
maintained tryparedoxin (10 µM) to its reduced form (see panel E). Reactions were carried out 21 
in 100 mM Tris-HCl pH 7.5, 2 mM EDTA buffer containing NADPH (300 µM), trypanothione 22 
reductase (2 U ml-1) and T(SH)2 (100 µM), to generate reduced tryparedoxin, and different 23 
concentrations of TbMSRA (0.05-3.5 µM) or TbMSRB (4-270 µM). Assays were initiated by 24 
addition of N-AcMetSO (5 mM) to reactions. (C). The MetSO isomer specificity of TbMSRA 25 
27 
 
and TbMSRB (20 µM) was performed using L-Met(S)SO or N-AcMet(R)SO (both 5 mM) as 1 
substrate (see Materials and Methods). The data are presented as mean % activity values (± 2 
standard deviations) derived from three independent experiments relative to assays performed 3 
using racemic L-MetSO (5 mM) as substrate. (D). Proposed scheme for the metabolism of 4 
Met(R)SO via a tryparedoxin-mediated TbMSRB pathway. Tryparedoxin (TXNI) acts as a 5 
redox shuttle between trypanothione and TbMSRB. Trypanothione disulfide (TS2) is converted 6 
to dihydrotrypanothione (T[SH]2) at the expense of NADPH by the activity of trypanothione 7 
reductase (TR) with “red” and “oxi” representing the reduced and oxidized form of 8 
proteins/substrates, respectively. The interactions of TbMSRB with TXNI (reaction I) and 9 
Met(R)SO (reaction II) are indicated. Kinetic parameters of recombinant TbMSRs is shown in 10 
the associated Table. To study Reaction I, the interaction between TXNI with TbMSRB, 11 
TbMSR activity was assayed as described in panel B using different concentrations of TXN1 12 
(0.3-20 µM) and a fixed concentration of N-AcMet(R)SO (2.5 mM). For Reaction II, the 13 
interaction between TbMSRB with N-AcMet(R)SO, TbMSR activity was assayed as described 14 
in panel B using a fixed concentration of TXN1 (10 µM) and different concentrations of N-15 
AcMet(R)SO (40-2500 µM). *Data relating to TbMSRA activity taken from Arias et al 2011 16 
[27] . 17 
 18 
Figure 3. Yeast complementation assay demonstrates substrate preference of T. brucei 19 
MSRs. The growth of S. cerevisiae GY202 triple mutant (ΔmsrA ΔmsrB ΔfRmsr) transformed 20 
with plasmids that facilitate expression of TbmsrA (msrA) or TbmsrB (msrB) on YNB agar the 21 
vectorplus dextrose agar supplemented with Met or different MetSOs was compared against 22 




Figure 4. Localisation of TbMSRs in bloodstream form T. brucei. (A). Expression of GFP 1 
tagged TbMSRs was examined by probing a blot containing cell lysates from T. brucei wild 2 
type (lane 1) and TbMSRA-GFP or TbMSRB-GFP expressing cells (lanes 2 and 3 respectively) 3 
using an anti-GFP antibody (upper panel). Protein from 1 x 107 cells was loaded in each track 4 
and equal loading verified by Coomassie staining (lower panel). (B). T. brucei expressing 5 
untagged GFP. The blue spots correspond to the nuclear (N) and mitochondrial (K) genomes 6 
of a trypanosome expressing GFP alone. (C). T. brucei cells expressing TbMSRA-GFP (panel 7 
2) were co-stained with DAPI (panel 1) with the merged signals (panel 3) and phase image 8 
(panel 4) shown. (D). T. brucei cells expressing TbMSRB-GFP (panel 2) were co-stained with 9 
DAPI (panel 1) and Mitotraker (TM; panel 3). The merged GFP/DAPI/Mitotraker signals 10 
(panel 4) and phase image (panel 5) are shown, with the yellow pattern in panel 4 revealing the 11 
co-localisation on TbMSRB-GFP and Mitotraker. Scale bar in B, C and D = 5 µm. 12 
 13 
Figure 5. Phenotypic analysis of RNAi cell lines. (A). The TbmsrA or TbmsrB transcript 14 
levels from non-induced cells (dark grey) and trypanosomes induced for 48 hours to undergo 15 
RNAi (light grey) was assessed by qPCR and compared against the expression level of a 16 
standardized control (Tbtert). The relative fold difference, as judged by 2-(ΔΔCT) from 17 
reactions performed in triplicate ± standard deviation, was plotted as a measure of the relative 18 
expression level. The difference in relative expression levels between the non-induced and 19 
induced lines was judged to be statistically significant (P <0.01), as assessed by the Student’s 20 
t test. The TbmsrA or TbmsrB mRNAs were both ~3.5-fold lower in the corresponding RNAi 21 
line relative to controls. (B). Growth of cells induced to undergo RNAi (dashed lines) targeting 22 
the TbmsrA or TbmsrB transcript was compared against non-induced cultures (solid line). The 23 
growth patterns shown relate to a single clone. Two other clones analysed in parallel exhibited 24 
the same profiles. (C). The BSF RNAi-TbmsrA and RNAi-TbmsrB lines were grown for 24 25 
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hours in the presence of tetracycline (1 µg ml– 1) (square, dotted line), seeded at 1 x 104 ml–1 1 
and then exposed to various concentrations of H2O2 (12.5–1000 µM): where applicable, RNAi 2 
induction was maintained in peroxide treated cultures by addition of fresh tetracycline to the 3 
growth medium. After 3 days at 37ₒC, resazurin (2.5 µg) was added to each culture and used to 4 
determine cell density (Experimental Procedures). Untreated (circles, solid line) and wild type 5 
parasites were analysed in parallel. From the resultant dose response curves, the EC50 of each 6 
line towards H2O2 was calculated. All data points are means for experiments performed in 7 
quadruplicate ± standard deviation. The difference in susceptibility to H2O2 displayed by the 8 
tetracycline-treated and untreated RNAi-TbmsrA cells as judge by EC50 values was statistically 9 
significant (P < 0.0001), as assessed by Student's t test. 10 
 11 
Figure 6. Overexpression of TbMSRs in bloodstream form T. brucei. (A). Expression of -12 
myc (9e10) tagged TbMSRs was examined by probing a blot containing cell lysates from T. 13 
brucei wild type (lane 1) and TbMSRA-9e10 or TbMSRB-9e10 expressing cells (lanes 2 and 14 
3 respectively) using c-myc (9e10) anti-serum (upper panel). Protein from 1 x 107 cells was 15 
loaded in each track and equal loading verified by Coomassie staining (lower panel). (B). The 16 
T. brucei TbmsrA-9e10 and TbmsrB-9e10 lines were grown for 24 hours in the presence of 17 
tetracycline (1 µg ml– 1) (diamond, dotted line), seeded at 1 x 104 ml–1 and then exposed to 18 
various concentrations of H2O2 (50–500 µM). After 3 days at 37
ₒC, resazurin (2.5 µg) was 19 
added to each culture and used to determine cell density (Experimental Procedures). Untreated 20 
(circles, solid line) and wild type parasites were analysed in parallel. From the resultant dose 21 
response curves, the EC50 of each line towards H2O2 was calculated. All data points are means 22 
for experiments performed in quadruplicate ± standard deviation. The difference in 23 
susceptibility to H2O2 displayed by the tetracycline-treated and untreated TbmsrA-9e10 cells as 24 
judge by EC50 values was statistically significant (P < 0.0001), as assessed by Student's t test. 25 
Figure 1.
Figure 2.
Figure 3.
Figure 4.
Figure 5.
Figure 6.
